{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "26194509-66fb-4e01-b3c6-47c7952a13c3",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "import os\n",
    "from dotenv import load_dotenv, find_dotenv\n",
    "\n",
    "load_dotenv(find_dotenv(usecwd=True))\n",
    "\n",
    "BASE_URL = \"https://gigachat.devices.sberbank.ru/api/v1\"\n",
    "#base_gg = \"https://router.huggingface.co/v1\"\n",
    "#\"http://a6k2.dgx:34000/v1\"\n",
    "\n",
    "BASE_URL = \"https://router.huggingface.co/v1\"\n",
    "\n",
    "#\"qwen3-32b\"\n",
    "# gigachat/GigaChat\n",
    "MODEL_NAME = os.getenv(\"MODEL_NAME\", 'GigaChat')\n",
    "\n",
    "\n",
    "\n",
    "MODEL_NAME_HF ='meta-llama/Llama-3.3-70B-Instruct'\n",
    "MODEL_NAME_HF ='Qwen/Qwen3-32B'\n",
    "\n",
    "MODEL_TEMPERATURE_HF =1\n",
    "\n",
    "os.environ[\"OPENAI_API_KEY\"] = os.getenv(\"GIGACHAT_AUTH\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "6f2862e1-9f3d-4188-8bbc-9a15817cd8f0",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'MDE5YmM2MjctOWU5ZS03OWE0LWE0OGYtY2FhMTU4MzYxZDgzOjJmNWUxMzMzLTNlYzMtNGI1Ni04OGZiLTRhMGIxNzFjNzFkMw=='"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "os.getenv(\"OPENAI_API_KEY\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "e14f07d4-cfbd-4129-8f11-5bf5c74d31cf",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "from langchain_community.document_loaders import PyMuPDFLoader\n",
    "from pydantic import BaseModel, Field\n",
    "from langchain_core.output_parsers import PydanticOutputParser, StrOutputParser, BaseOutputParser\n",
    "from textwrap import dedent\n",
    "\n",
    "from langchain_openai import ChatOpenAI\n",
    "from langchain_core.messages import HumanMessage\n",
    "from langchain_core.prompts import ChatPromptTemplate\n",
    "import httpx\n",
    "import json\n",
    "import requests\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "import re\n",
    "\n",
    "from langchain_pymupdf4llm import PyMuPDF4LLMLoader, PyMuPDF4LLMParser\n",
    "import pymupdf4llm\n",
    "\n",
    "from trialmind.pubmed import pmid2papers, PubmedAPIWrapper, pmid2biocxml, parse_bioc_xml\n",
    "from trialmind.api import StudyCharacteristicsExtraction, ScreeningCriteriaGeneration\n",
    "from trialmind.retrievers import split_text_into_chunks\n",
    "\n",
    "\n",
    "import time\n",
    "import extract\n",
    "%load_ext autoreload\n",
    "%autoreload 2\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5301994a-a15c-47ce-b6b8-ce0ceae9e67b",
   "metadata": {
    "jp-MarkdownHeadingCollapsed": true,
    "tags": []
   },
   "source": [
    "### clinical trials"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "7eb1ed4e-88ad-454d-a841-868d8d03925b",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "('Colorectal cancer',\n",
       " ['Crizotinib',\n",
       "  'Lorlatinib',\n",
       "  'Necitumumab',\n",
       "  'Nimotuzumab',\n",
       "  'Panitumumab',\n",
       "  'Cetuximab',\n",
       "  'Brigatinib',\n",
       "  'Ramucirumab',\n",
       "  'Pomalidomide',\n",
       "  'Toremifene',\n",
       "  'Denosumab',\n",
       "  'Duvelisib',\n",
       "  'Inavolitib',\n",
       "  'Bevacizumab',\n",
       "  'Anastrozole',\n",
       "  'Exemestane'])"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "file_path = \"docs/CC_215_L00_DL_fusion_fixed_oncobox_ru.pdf\"\n",
    "fin_condition, treatements_eng = extract.info_from_doc(file_path)\n",
    "fin_condition, treatements_eng"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e3c68437-54be-4611-9aa0-d7f6a379a924",
   "metadata": {},
   "source": [
    "1. загрузить док\n",
    "2. взять 1-ую страницу; рег.выражениями взять диагноз\n",
    "-- с ЛЛМ перевести на англ.\n",
    "3. найти страницу с таблицей; или взять таблицы с PyMuPDFLoader\n",
    "4. извлечь таблицу"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "e04c59f8-3cbd-4491-9154-56edbc434e12",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Crizotinib OR Lorlatinib OR Necitumumab OR Nimotuzumab OR Panitumumab OR Cetuximab OR Brigatinib OR Ramucirumab OR Pomalidomide OR Toremifene OR Denosumab OR Duvelisib OR Inavolitib OR Bevacizumab OR Anastrozole OR Exemestane'"
      ]
     },
     "execution_count": 63,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "' OR '.join(treatements_eng)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "6b530143-823c-495a-8e2a-7039031a23b2",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "0b55cf5c-e883-4a42-ad8f-08633873be8f",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "all_studies = extract.get_clinicaltrials(fin_condition, \n",
    "                                      #' OR '.join(treatements_eng), \n",
    "                                       treatements_eng[0],  \n",
    "                                      max_studies=100)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "30556d38-abf1-4810-a15e-46d3eef966dc",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>title</th>\n",
       "      <th>status</th>\n",
       "      <th>conditions</th>\n",
       "      <th>study_type</th>\n",
       "      <th>phases</th>\n",
       "      <th>interventions</th>\n",
       "      <th>outcomes</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT02465060</td>\n",
       "      <td>Targeted Therapy Directed by Genetic Testing i...</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>[Advanced Lymphoma, Advanced Malignant Solid N...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[adavosertib, afatinib, afatinib dimaleate, bi...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT03947385</td>\n",
       "      <td>Study of IDE196 in Patients With Solid Tumors ...</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>[Metastatic Uveal Melanoma, Cutaneous Melanoma...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1, PHASE2]</td>\n",
       "      <td>[ide196, binimetinib, crizotinib]</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT02568267</td>\n",
       "      <td>Basket Study of Entrectinib (RXDX-101) for the...</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>[Breast Cancer, Cholangiocarcinoma, Colorectal...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[entrectinib]</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT06214793</td>\n",
       "      <td>Taletrectinib in Previously Treated Metastatic...</td>\n",
       "      <td>SUSPENDED</td>\n",
       "      <td>[Breast Cancer, Metastatic Breast Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[taletrectinib]</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT03792568</td>\n",
       "      <td>ALK Inhibitor in Metastatic Colorectal Cancer ...</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>[Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[NA]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT05725200</td>\n",
       "      <td>Study to Investigate Outcome of Individualized...</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>[Metastatic Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[alectinib, cetuximab, crizotinib, dasatinib, ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>True</td>\n",
       "      <td>NCT02510001</td>\n",
       "      <td>MEK and MET Inhibition in Colorectal Cancer</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>[Solid Tumor, Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1]</td>\n",
       "      <td>[pf-02341066, pd-0325901, binimetinib]</td>\n",
       "      <td>[{'type': 'PRIMARY', 'title': 'Maximal Tolerat...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   results           id                                              title  \\\n",
       "0    False  NCT02465060  Targeted Therapy Directed by Genetic Testing i...   \n",
       "1    False  NCT03947385  Study of IDE196 in Patients With Solid Tumors ...   \n",
       "2    False  NCT02568267  Basket Study of Entrectinib (RXDX-101) for the...   \n",
       "3    False  NCT06214793  Taletrectinib in Previously Treated Metastatic...   \n",
       "4    False  NCT03792568  ALK Inhibitor in Metastatic Colorectal Cancer ...   \n",
       "5    False  NCT05725200  Study to Investigate Outcome of Individualized...   \n",
       "6     True  NCT02510001        MEK and MET Inhibition in Colorectal Cancer   \n",
       "\n",
       "                  status                                         conditions  \\\n",
       "0  ACTIVE_NOT_RECRUITING  [Advanced Lymphoma, Advanced Malignant Solid N...   \n",
       "1             RECRUITING  [Metastatic Uveal Melanoma, Cutaneous Melanoma...   \n",
       "2  ACTIVE_NOT_RECRUITING  [Breast Cancer, Cholangiocarcinoma, Colorectal...   \n",
       "3              SUSPENDED          [Breast Cancer, Metastatic Breast Cancer]   \n",
       "4                UNKNOWN                                [Colorectal Cancer]   \n",
       "5             RECRUITING                     [Metastatic Colorectal Cancer]   \n",
       "6              COMPLETED                   [Solid Tumor, Colorectal Cancer]   \n",
       "\n",
       "       study_type            phases  \\\n",
       "0  INTERVENTIONAL          [PHASE2]   \n",
       "1  INTERVENTIONAL  [PHASE1, PHASE2]   \n",
       "2  INTERVENTIONAL          [PHASE2]   \n",
       "3  INTERVENTIONAL          [PHASE2]   \n",
       "4  INTERVENTIONAL              [NA]   \n",
       "5  INTERVENTIONAL          [PHASE2]   \n",
       "6  INTERVENTIONAL          [PHASE1]   \n",
       "\n",
       "                                       interventions  \\\n",
       "0  [adavosertib, afatinib, afatinib dimaleate, bi...   \n",
       "1                  [ide196, binimetinib, crizotinib]   \n",
       "2                                      [entrectinib]   \n",
       "3                                    [taletrectinib]   \n",
       "4                                                 []   \n",
       "5  [alectinib, cetuximab, crizotinib, dasatinib, ...   \n",
       "6             [pf-02341066, pd-0325901, binimetinib]   \n",
       "\n",
       "                                            outcomes  \n",
       "0                                                NaN  \n",
       "1                                                NaN  \n",
       "2                                                NaN  \n",
       "3                                                NaN  \n",
       "4                                                NaN  \n",
       "5                                                NaN  \n",
       "6  [{'type': 'PRIMARY', 'title': 'Maximal Tolerat...  "
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_studies"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "37f1ccfb-f682-457e-bf61-1bed5aad563c",
   "metadata": {
    "jp-MarkdownHeadingCollapsed": true,
    "tags": []
   },
   "source": [
    "### outcome results\n",
    "Взяли все результаты, отдельно сохранили испытания с результатами, и з них отбираем рез-ты только с unit==participants\n",
    "\n",
    "filter by interventional study type?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 251,
   "id": "c5e73eef-7cac-4115-93c7-34ba0ee46532",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'type': 'PRIMARY',\n",
       "  'title': 'Clinical Response to Binimetinib Combined With PF-02341066',\n",
       "  'description': 'To investigate response to treatment with RPII dose of Binimetinib with Crizotinib (PF-02341066), in patients with a) RASMT CRC or b) RASWT/cMET mut amplified CRC or c) RASWT/c-MET over-expressed CRC, as defined by stable, partially or completely responding disease, per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\\\>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase (\\\\>=20%) to qualify for Progressive Disease; Overall Response (OR) = CR + PR + SD',\n",
       "  'populationDescription': 'Evaluable patients for the primary outcome are those patients who complete a response assessment after cycle 1 of treatment, or who progress early on treatment. 30 of the 36 recruited patients had a response assessment after cycle 1 or progressed early on treatment, and hence these 30 patients are evaluable for the primary analysis.',\n",
       "  'reportingStatus': 'POSTED',\n",
       "  'paramType': 'COUNT_OF_PARTICIPANTS',\n",
       "  'unitOfMeasure': 'Participants',\n",
       "  'timeFrame': 'Dose Expansion phase: change from baseline and up to 12 months.',\n",
       "  'groups': [{'id': 'OG000',\n",
       "    'title': 'Dose Expansion Phase',\n",
       "    'description': 'Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.\\n\\nPF-02341066: PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously\\n\\nBinimetinib: Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days'}],\n",
       "  'denoms': [{'units': 'Participants',\n",
       "    'counts': [{'groupId': 'OG000', 'value': '30'}]}],\n",
       "  'classes': [{'categories': [{'title': 'Stable Disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '7'}]},\n",
       "     {'title': 'Progressive Disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '22'}]},\n",
       "     {'title': 'Early death from malignant disease',\n",
       "      'measurements': [{'groupId': 'OG000', 'value': '1'}]}]}]}]"
      ]
     },
     "execution_count": 251,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "outcome_participants = [obj for item_main in results_studies for obj in item_main['resultsSection']['outcomeMeasuresModule'\n",
    "                                           ]['outcomeMeasures'\n",
    "                                            ] if(obj.get('unitOfMeasure','') == 'Participants')] \n",
    "outcome_participants"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9303a48c-9dd0-418b-8c9f-3708b4f9148a",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 273,
   "id": "db6360d3-76fa-4607-8764-0a705af4464c",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<think>\n",
      "\n",
      "</think>\n",
      "\n",
      "Here is a concise summary of the efficiency statistics for the clinical response to Binimetinib combined with PF-02341066 (Crizotinib) in the Dose Expansion Phase:\n",
      "\n",
      "- **Total Evaluable Patients**: 30 participants.\n",
      "- **Stable Disease (SD)**: 7 patients (23.3%).\n",
      "- **Progressive Disease (PD)**: 22 patients (73.3%).\n",
      "- **Early Death from Malignant Disease**: 1 patient (3.3%).\n",
      "\n",
      "These outcomes were assessed using RECIST v1.1 criteria after cycle 1 of treatment.\n"
     ]
    }
   ],
   "source": [
    "prompt2 = ChatPromptTemplate.from_messages([\n",
    "    (\"system\", \"You are a helpful medical assistant. Extract information about the efficiency statistics from each outcome measure. Give a concise description with percentages /no_think\"),\n",
    "    (\"human\", \"{text}\"),\n",
    "    # (\"ai\", \"Good.\")\n",
    "])\n",
    "\n",
    "chain2 = prompt2 | llm_reasoning\n",
    "response_res = await chain2.ainvoke({\"text\": outcome_participants[0]})\n",
    "print(response_res.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "84f5d879-2920-4ec3-bac4-5ae64fb55099",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "e706ee64-c65f-40a9-8606-8e71c97fa5d6",
   "metadata": {
    "jp-MarkdownHeadingCollapsed": true,
    "tags": []
   },
   "source": [
    "### results in a given format?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8f1d0545-8778-43fb-9af8-da1730e79453",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "class Info(BaseModel):\n",
    "    diagnose: str = Field(..., description=\"База клинических испытаний\")\n",
    "    treatments: str = Field(..., description=\"Высшие позиции рейтинга таргетных препаратов\")\n",
    "\n",
    "parser = PydanticOutputParser(pydantic_object=Info)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "1d5b0edc-bb8f-4fcd-b443-36745ad7eaf7",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "prompt = ChatPromptTemplate.from_messages([\n",
    "    (\n",
    "        \"system\", \n",
    "        dedent(\n",
    "            \"\"\"\n",
    "            You are a helpful assistant. \n",
    "            Your goal is to extract related information from the text provided by the user.\n",
    "            Return the information in the following JSON-format.\n",
    "            {fmt}\n",
    "            \"\"\"\n",
    "        )\n",
    "    ),\n",
    "    (\n",
    "        \"human\", \n",
    "        dedent(\n",
    "            \"\"\"\n",
    "            Text: {text}\"\n",
    "            \"\"\"\n",
    "        )\n",
    "    ),\n",
    "])\n",
    "chain = (\n",
    "    prompt \n",
    "    | llm_reasoning \n",
    "    | parser\n",
    ")\n",
    "\n",
    "\n",
    "response = await chain.ainvoke({\"text\": text, \"fmt\": parser.get_format_instructions()})\n",
    "print(response)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d963b7db-0c01-4b5f-af74-d7d566ae8a54",
   "metadata": {
    "tags": []
   },
   "source": [
    "### papers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "ceab5c26-765a-420c-82a6-8bfbacdb36f6",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(['40526090',\n",
       "  '35343863',\n",
       "  '38378070',\n",
       "  '37686423',\n",
       "  '36053834',\n",
       "  '34898475',\n",
       "  '37418240',\n",
       "  '37543570',\n",
       "  '34230141',\n",
       "  '36316649',\n",
       "  '36627781',\n",
       "  '40140597',\n",
       "  '34101765',\n",
       "  '37773318',\n",
       "  '41268440',\n",
       "  '38711893',\n",
       "  '34853656',\n",
       "  '40369167',\n",
       "  '34766064',\n",
       "  '38212428',\n",
       "  '36129915',\n",
       "  '34036227',\n",
       "  '40211189',\n",
       "  '41213063',\n",
       "  '36801912'],\n",
       " 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=(Colorectal cancer)+AND+(Crizotinib)&retmax=25&retmode=json&api_key=6892c4129cef143ff92d11533848d2e0d908',\n",
       " '67')"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "search_api = PubmedAPIWrapper()\n",
    "# page_size is the max number of records to return!!!! not pages!\n",
    "tmp_inputs = {\n",
    "        \"page_size\": 25,\n",
    "        \"keyword_map\": {'conditions':[fin_condition], \n",
    "                        'treatments':[treatements_eng[0]]\n",
    "                       },\n",
    "        \"keywords\": {\n",
    "            \"OPERATOR\": 'AND'\n",
    "        }\n",
    "}\n",
    "pubmed_api_key= '6892c4129cef143ff92d11533848d2e0d908'#os.getenv(\"PUBMED_API_KEY\", '')\n",
    "time.sleep(.5)\n",
    "response = search_api.build_search_query_and_get_pmid(tmp_inputs, \n",
    "                                                      api_key=pubmed_api_key)\n",
    "response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "a54a4f2c-d723-4a4a-a1b1-77eb50eeaea8",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PMID</th>\n",
       "      <th>Journal</th>\n",
       "      <th>Year</th>\n",
       "      <th>Month</th>\n",
       "      <th>Day</th>\n",
       "      <th>Title</th>\n",
       "      <th>Publication Type</th>\n",
       "      <th>Authors</th>\n",
       "      <th>Abstract</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>40526090</td>\n",
       "      <td>Oncotarget</td>\n",
       "      <td>2025</td>\n",
       "      <td>Jun</td>\n",
       "      <td>17</td>\n",
       "      <td>Case Report WIN-MTB-2023001 WIN International ...</td>\n",
       "      <td>Journal Article, Case Reports</td>\n",
       "      <td>Alberto Hernando-Calvo, Razelle Kurzrock, Nadi...</td>\n",
       "      <td>Heavily pretreated metastatic colorectal cance...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>35343863</td>\n",
       "      <td>Expert opinion on therapeutic patents</td>\n",
       "      <td>2022</td>\n",
       "      <td>Jun</td>\n",
       "      <td></td>\n",
       "      <td>An updated patent review of small-molecule ROS...</td>\n",
       "      <td>Journal Article, Review</td>\n",
       "      <td>Meng Liu, Jintian Dai, Mudan Wei, Qingshan Pan...</td>\n",
       "      <td>C-ros oncogene 1 (ROS1) is the sole member of ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>38378070</td>\n",
       "      <td>Experimental and molecular pathology</td>\n",
       "      <td>2024</td>\n",
       "      <td>Apr</td>\n",
       "      <td></td>\n",
       "      <td>TBX15 and SDHB expression changes in colorecta...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Melika Golozar, Ali Valipour Motlagh, Mohammad...</td>\n",
       "      <td>Alterations in the expression of certain genes...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>37686423</td>\n",
       "      <td>International journal of molecular sciences</td>\n",
       "      <td>2023</td>\n",
       "      <td>Sep</td>\n",
       "      <td>03</td>\n",
       "      <td>Targeted Therapy for Cancers: From Ongoing Cli...</td>\n",
       "      <td>Journal Article, Review</td>\n",
       "      <td>Ha Yeong Choi, Ji-Eun Chang</td>\n",
       "      <td>The development of targeted therapies has revo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>36053834</td>\n",
       "      <td>International journal of cancer</td>\n",
       "      <td>2022</td>\n",
       "      <td>Dec</td>\n",
       "      <td>15</td>\n",
       "      <td>ROS1 genomic rearrangements are rare actionabl...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Dilara Akhoundova, Saskia Hussung, Smruthy Siv...</td>\n",
       "      <td>c-Ros oncogene 1, receptor tyrosine kinase (RO...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       PMID                                      Journal  Year Month Day  \\\n",
       "0  40526090                                   Oncotarget  2025   Jun  17   \n",
       "1  35343863        Expert opinion on therapeutic patents  2022   Jun       \n",
       "2  38378070         Experimental and molecular pathology  2024   Apr       \n",
       "3  37686423  International journal of molecular sciences  2023   Sep  03   \n",
       "4  36053834              International journal of cancer  2022   Dec  15   \n",
       "\n",
       "                                               Title  \\\n",
       "0  Case Report WIN-MTB-2023001 WIN International ...   \n",
       "1  An updated patent review of small-molecule ROS...   \n",
       "2  TBX15 and SDHB expression changes in colorecta...   \n",
       "3  Targeted Therapy for Cancers: From Ongoing Cli...   \n",
       "4  ROS1 genomic rearrangements are rare actionabl...   \n",
       "\n",
       "                Publication Type  \\\n",
       "0  Journal Article, Case Reports   \n",
       "1        Journal Article, Review   \n",
       "2                Journal Article   \n",
       "3        Journal Article, Review   \n",
       "4                Journal Article   \n",
       "\n",
       "                                             Authors  \\\n",
       "0  Alberto Hernando-Calvo, Razelle Kurzrock, Nadi...   \n",
       "1  Meng Liu, Jintian Dai, Mudan Wei, Qingshan Pan...   \n",
       "2  Melika Golozar, Ali Valipour Motlagh, Mohammad...   \n",
       "3                        Ha Yeong Choi, Ji-Eun Chang   \n",
       "4  Dilara Akhoundova, Saskia Hussung, Smruthy Siv...   \n",
       "\n",
       "                                            Abstract  \n",
       "0  Heavily pretreated metastatic colorectal cance...  \n",
       "1  C-ros oncogene 1 (ROS1) is the sole member of ...  \n",
       "2  Alterations in the expression of certain genes...  \n",
       "3  The development of targeted therapies has revo...  \n",
       "4  c-Ros oncogene 1, receptor tyrosine kinase (RO...  "
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_papers = pmid2papers(pmid_list=response[0], api_key=pubmed_api_key)\n",
    "df_papers[0].head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "dd4f5664-3983-4bbb-af9f-7f460b87e5e3",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "('Colorectal cancer', ['Crizotinib', 'Lorlatinib'])"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "fin_condition, treatements_eng"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f15bedd0-7b97-4696-ac71-2b9ddc4ef0d6",
   "metadata": {},
   "source": [
    "### extract results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "365da54d-32aa-445c-b27b-0b6b2ae80cf6",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "fin_condition = 'Colorectal cancer'\n",
    "treatements_eng =  ['Crizotinib','Lorlatinib',]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "66ffb1de-672b-4c10-acfc-bcade11f8c7d",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "D:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\urllib3\\connectionpool.py:1097: InsecureRequestWarning: Unverified HTTPS request is being made to host 'ngw.devices.sberbank.ru'. Adding certificate verification is strongly advised. See: https://urllib3.readthedocs.io/en/latest/advanced-usage.html#tls-warnings\n",
      "  warnings.warn(\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "'eyJjdHkiOiJqd3QiLCJlbmMiOiJBMjU2Q0JDLUhTNTEyIiwiYWxnIjoiUlNBLU9BRVAtMjU2In0.tdQZdmvDbOOLrIw7xxHWFvKWIgUAIHrki5J3GgVvhDLY0XYzVx_fo-jEOtVUWvYt8sQiqGjLJCYI3YRQ_yke0dGy9X_5PBhSlYB25_OFZtYjA2tfNBCzTBaqjCA-DVOTVoP00G-obTMwvF0FELDWZE0SoFMwY5xyUfewGD330wWDY6MHfj-eBfpVEaoRGsL29bvhW0kOZH_cNCVZQaIUxHlrNTZfSTT_o9eB15bDZCyNqXGPnr6OvV7TCQysxG05x72lmXxsCVyNmMUEf7A_AfecSLf0OzYEZms9-9H75gTAd1Ufq0nJiK_teYa4rVCycCGZYXAHanP9pn1gY8QbAg.Tg-XTafdjmhvtnLQq-VYPw.gwoEWZR05lcGAdIta3d4ilKYSvQi4UVjKYWPxfV3focdcDAP-g715vCg-3f6xmfV59CMXOxfv7KScySMUybQLSc9-qYMD2sPVwtKNOC0Ly9X6QRtrLAjnS5EOZc2pXw21qLX9_CsQdUzCtV8N7VpIeF6q7UHuCGdtLJyMSOmHr_PltEes9aaBQFtd9GYYeviXBrsnX2BK2B6O_arrqFBR44i_HvyYJcMIWYkot-XKTqs_-K8AoGEBG03VvKOQO9jGC3Ln9Yoy0P6IWXy2sBEdLxEMYvk7Ms4AQaRQtnckAcxaEs675BdoqdWOfPopreE64mrLJhmmq9GhOM6AYbv7XjuhH9_IMdLo-kjRBljQmMrZyBtoU4GUIXXscpfWcfYr3AxmA5absl-RzatCarQ-M3XUFUmrnZ-wUXvBTY5oNkFZCZ_ZOhIzAuK_9zVPQobGijNnyA-tlrcJ_QsFeg3-LMIpkFYFez_TsYC3mTe904kQy8f2KwlyZSTuk5YFKJ-SY1prl9GFsTmqnyO5uAbURUJv_ou5Ou1VTfdIY60KVkvTFqainYV5sxCiG4gRnuvFaYkrxVOiGABU-9HDOmcewUTOHg9VO5ZOQsHMXZZgiY5jTCbj1Z7uKQMZm5vxZB8dU_Zhuhv6_1BVhJ0aDUrD1fJV8KIA6gDWbc-00Sb8miRDkJ55KNpU1GnPHjuVF8e2onxS3wLugATRJiJ1oBSg6Ms3HyYWG0AtvaM1WqngZs.-N5pB8Red6NDo-nDBNwKXiu5-t9cspTsi6w6DqMjqQg'"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import requests\n",
    "import uuid\n",
    "\n",
    "url = \"https://ngw.devices.sberbank.ru:9443/api/v2/oauth\"\n",
    "# Создадим идентификатор UUID (36 знаков)\n",
    "rq_uid = str(uuid.uuid4())\n",
    "payload={\n",
    "  'scope': 'GIGACHAT_API_PERS'\n",
    "}\n",
    "headers = {\n",
    "  'Content-Type': 'application/x-www-form-urlencoded',\n",
    "  'Accept': 'application/json',\n",
    "  'RqUID': rq_uid,\n",
    "  'Authorization': f'Basic {os.getenv(\"GIGACHAT_AUTH\")}'\n",
    "}\n",
    "\n",
    "response = requests.request(\"POST\", url, headers=headers, data=payload, verify=False)\n",
    "os.environ[\"OPENAI_API_KEY\"] = response.json()['access_token']\n",
    "\n",
    "os.getenv(\"OPENAI_API_KEY\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "720ecef2-268b-4b8e-8241-96b44d26d0bf",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "from openai import OpenAI"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "4e632a26-387b-4c21-b67c-5408ce327484",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "os.environ[\"BASE_URL\"] = \"https://gigachat.devices.sberbank.ru/api/v1\"\n",
    "os.environ[\"MODEL_NAME\"] ='GigaChat'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "be0895aa-5d22-4c08-b855-21edebeff92f",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "ChatCompletion(id=None, choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='**Тропинка вдаль бежит,**\\n**Листья шепчут о счастье,**\\n**Солнце светит в вышине —**\\n**Жизнь прекрасна сейчас!**\\n\\n**Сердцу тихо поют ручьи,**\\n**Радость в сердце живёт,**\\n**И мечты ведут меня**\\n**К сияющим высотам.**', refusal=None, role='assistant', annotations=None, audio=None, function_call=None, tool_calls=None))], created=1770294685, model='GigaChat:2.0.28.2', object='chat.completion', service_tier=None, system_fingerprint=None, usage=CompletionUsage(completion_tokens=73, prompt_tokens=20, total_tokens=93, completion_tokens_details=None, prompt_tokens_details=None, precached_prompt_tokens=2))"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "openai_client = OpenAI(\n",
    "    base_url=os.getenv(\"BASE_URL\"),\n",
    "    api_key=os.getenv(\"OPENAI_API_KEY\"),\n",
    "    http_client=httpx.Client(http2=True, verify=False)\n",
    ")\n",
    "\n",
    "response = openai_client.chat.completions.create(\n",
    "        model=os.getenv(\"MODEL_NAME\"),\n",
    "        messages=[{\"role\": \"user\", \"content\": \"You are a helpful assistant. Create a short poem\"}],  # Ensure messages is a list\n",
    "        temperature=0\n",
    "    )\n",
    "response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "edf59fa4-0dbb-4fd6-8af9-dbaa5190e776",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'https://gigachat.devices.sberbank.ru/api/v1'"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "os.getenv(\"BASE_URL\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "f7987e16-3579-4cf1-b9a0-ef66a903aeb9",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "https://gigachat.devices.sberbank.ru/api/v1\n",
      "https://gigachat.devices.sberbank.ru/api/v1/\n",
      "{\n",
      "  \"ELIGIBILITY_ANALYSIS\": [\n",
      "    // Eligibility Criteria Rationales\n",
      "    \"Patients must have colorectal cancer — Studies focusing on other types of cancers would not provide relevant data.\",\n",
      "    \"Studies involving patients receiving crizotinib as an intervention — Exclusion of studies using different treatments ensures consistency in comparison.\",\n",
      "    \"Comparative studies including a control group receiving standard therapy or placebo — Comparisons against standard care or placebo ensure meaningful outcomes.\",\n",
      "    \"Outcomes related to survival rates, response rates, toxicity profiles, or quality-of-life measures — These outcomes directly relate to patient management and treatment effectiveness.\",\n",
      "    \"Published studies from peer-reviewed journals — Ensures reliability and validity of findings.\"\n",
      "  ],\n",
      "  \"TITLE_CRITERIA\": [\n",
      "    // Binary Title-Based Questions\n",
      "    \"Does the title mention 'colorectal cancer'?\",\n",
      "    \"Does the title mention 'crizotinib'?\",\n",
      "    \"Is there any indication in the title that the study compares crizotinib to another treatment?\"\n",
      "  ],\n",
      "  \"CONTENT_CRITERIA\": [\n",
      "    // Binary Content-Based Questions\n",
      "    \"Are the methods section and results clearly described in the paper?\",\n",
      "    \"Does the study specify the type of colorectal cancer (e.g., adenocarcinoma)?\",\n",
      "    \"Were the outcomes measured over a sufficient duration to assess long-term effects?\"\n",
      "  ]\n",
      "}\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'title_criteria': [], 'content_criteria': [], 'eligibility_analysis': []}"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# test the apis\n",
    "\n",
    "api = ScreeningCriteriaGeneration()\n",
    "ecs = api.run(\n",
    "    population = f\"Patients with {fin_condition} undergoing treatment with {treatements_eng[0]}\",\n",
    "    intervention = f\"{treatements_eng[0]}\",\n",
    "    comparator = \"\",\n",
    "    outcome = \"\",\n",
    "    llm = os.getenv(\"MODEL_NAME\"),\n",
    "    num_title_criteria=3,\n",
    "    num_abstract_criteria=3,\n",
    "    thinking=False,\n",
    ")\n",
    "ecs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "f2858acb-a1e3-4d89-b8af-f1b7ce0cf1d4",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.: Heavily pretreated metastatic colorectal cancer (mCRC) poses significant therapeutic challenges. Advances in molecular profiling enables personalized strategies. We present a 62-year-old male with mCRC harboring',\n",
       " 'An updated patent review of small-molecule ROS1 kinase inhibitors (2015-2021).: C-ros oncogene 1 (ROS1) is the sole member of the ROS1 receptor tyrosine kinase (ROS1-RTK) family, which is involved in the formation of non-small cell lung cancer (NSCLC), gastric adenocarcinoma, colorectal cancer, and other malignant tumors. At present, only crizotinib was approved for the treatment of advanced ROS1-positive NSCLC, and there have been reports of ROS1 mutations resulting in drug resistance. Consequently, it is necessary to develop new generations of inhibitors to overcome the existing problems.\\nThis review summarizes the inhibitors with ROS1 inhibitory activity which are undergoing clinical trials and recent advances in patented ROS1 small molecular inhibitors from 2015 to 2021.\\nROS1 rearrangements have been found in approximately 1%-2% of patients with NSCLC. Since the approval of crizotinib as multi-targeted ALK/MET/ROS1 kinase inhibitor for ALK-mutated NSCLC therapy, the researchers are focusing on ROS1-mutated tumors, especially NSCLC. However, drug-resistant mutations have already been found in clinical application. Therefore, it is still urgent to develop new generation of ROS1 inhibitors.',\n",
       " 'TBX15 and SDHB expression changes in colorectal cancer serve as potential prognostic biomarkers.: Alterations in the expression of certain genes could be associated with both patient mortality rates and drug resistance. This study aimed to identify genes in colorectal cancer (CRC) that potentially serve as hub genes influencing patient survival rates. RNA-Seq data were downloaded from the cancer genome atlas database, and differential expression analysis was performed between tumors and healthy controls. Through the utilization of univariate and multivariate Cox regression analyses, in combination with the MCODE clustering module, the genes whose expression changes were related to survival rate and the hub genes related to them were identified. The mortality risk model was computed using the hub genes. CRC samples and the RT-qPCR method were utilized to confirm the outcomes. PharmacoGx data were employed to link the expression of potential genes to medication resistance and sensitivity. The results revealed the discovery of seven hub genes, which emerged as independent prognostic markers. These included HOXC6, HOXC13, HOXC8, and TBX15, which were associated with poor prognosis and overexpression, as well as SDHB, COX5A, and UQCRC1, linked to favorable prognosis and downregulation. Applying the risk model developed with the mentioned genes revealed a markedly higher incidence of deceased patients in the high-risk group compared to the low-risk group. RT-qPCR results indicated a decrease in SDHB expression and an elevation in TBX15 levels in cancer samples relative to adjacent healthy tissue. Also, PharmacoGx data indicated that the expression level of SDHB was correlated with drug sensitivity to Crizotinib and Dovitinib. Our findings highlight the potential association between alterations in the expression of genes such as HOXC6, HOXC13, HOXC8, TBX15, SDHB, COX5A, and UQCRC1 and increased mortality rates in CRC patients. As revealed by the PPI network, these genes exhibited the most connections with other genes linked to survival.']"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from trialmind.api import LiteratureScreening\n",
    "api = LiteratureScreening()\n",
    "\n",
    "papers = df_papers[0].iloc[:3][\"Title\"] + \": \" + df_papers[0].iloc[:3][\"Abstract\"].fillna(\"\") # important to fillna\n",
    "papers = papers.tolist()\n",
    "papers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "51d94360-c951-4e9a-b37f-8fc6e2eea203",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "e604d682-87c0-4bcb-97c0-0c4109f1bdd3",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "title_criteria = [\"Does the title mention 'colorectal cancer'?\",\n",
    "\"Does the title mention 'crizotinib'?\",\n",
    "\"Is there any indication in the title that the study compares crizotinib to another treatment?\"\n",
    "]\n",
    "\n",
    "content_criteria = [\"Are the methods section and results clearly described in the paper?\",\n",
    "\"Does the study specify the type of colorectal cancer (e.g., adenocarcinoma)?\",\n",
    "\"Were the outcomes measured over a sufficient duration to assess long-term effects?\"\n",
    "  ]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "54842268-da25-4f52-b604-fd1b0473a2e9",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "6e510df2-8174-4105-bcaa-00767e4560ba",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "ename": "ModuleNotFoundError",
     "evalue": "No module named 'langchain.pydantic_v1'",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mModuleNotFoundError\u001b[0m                       Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[32], line 1\u001b[0m\n\u001b[1;32m----> 1\u001b[0m ec_pred \u001b[38;5;241m=\u001b[39m \u001b[43mapi\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrun\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m      2\u001b[0m \u001b[43m    \u001b[49m\u001b[43mpopulation\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m \u001b[49m\u001b[38;5;124;43mf\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mPatients with \u001b[39;49m\u001b[38;5;132;43;01m{\u001b[39;49;00m\u001b[43mfin_condition\u001b[49m\u001b[38;5;132;43;01m}\u001b[39;49;00m\u001b[38;5;124;43m undergoing treatment with \u001b[39;49m\u001b[38;5;132;43;01m{\u001b[39;49;00m\u001b[43mtreatements_eng\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;241;43m0\u001b[39;49m\u001b[43m]\u001b[49m\u001b[38;5;132;43;01m}\u001b[39;49;00m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m      3\u001b[0m \u001b[43m    \u001b[49m\u001b[43mintervention\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m \u001b[49m\u001b[38;5;124;43mf\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;132;43;01m{\u001b[39;49;00m\u001b[43mtreatements_eng\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;241;43m0\u001b[39;49m\u001b[43m]\u001b[49m\u001b[38;5;132;43;01m}\u001b[39;49;00m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m      4\u001b[0m \u001b[43m    \u001b[49m\u001b[43mcomparator\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m      5\u001b[0m \u001b[43m    \u001b[49m\u001b[43moutcome\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m      6\u001b[0m \u001b[43m    \u001b[49m\u001b[43mllm\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m \u001b[49m\u001b[43mos\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mgetenv\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mMODEL_NAME\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m      7\u001b[0m \u001b[43m    \u001b[49m\u001b[43mcriteria\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m \u001b[49m\u001b[43mtitle_criteria\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m+\u001b[39;49m\u001b[43m \u001b[49m\u001b[43mcontent_criteria\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m      8\u001b[0m \u001b[43m    \u001b[49m\u001b[43mpapers\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m \u001b[49m\u001b[43mpapers\u001b[49m\u001b[43m[\u001b[49m\u001b[43m:\u001b[49m\u001b[38;5;241;43m3\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;66;43;03m# make for the top-100 for demo\u001b[39;49;00m\n\u001b[0;32m      9\u001b[0m \u001b[43m)\u001b[49m\n\u001b[0;32m     10\u001b[0m ec_pred\n",
      "File \u001b[1;32m~\\GitHub\\TrialMind-SLR\\trialmind\\api.py:367\u001b[0m, in \u001b[0;36mLiteratureScreening.run\u001b[1;34m(self, population, intervention, comparator, outcome, papers, criteria, llm, batch_size)\u001b[0m\n\u001b[0;32m    356\u001b[0m     batch_inputs\u001b[38;5;241m.\u001b[39mappend({\n\u001b[0;32m    357\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mP\u001b[39m\u001b[38;5;124m\"\u001b[39m: population,\n\u001b[0;32m    358\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mI\u001b[39m\u001b[38;5;124m\"\u001b[39m: intervention,\n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m    363\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mnum_criteria\u001b[39m\u001b[38;5;124m\"\u001b[39m: n_criteria\n\u001b[0;32m    364\u001b[0m     })\n\u001b[0;32m    366\u001b[0m \u001b[38;5;66;03m# call llm\u001b[39;00m\n\u001b[1;32m--> 367\u001b[0m \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21;01mlangchain\u001b[39;00m\u001b[38;5;21;01m.\u001b[39;00m\u001b[38;5;21;01mpydantic_v1\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mimport\u001b[39;00m BaseModel, validator, Field, conlist\n\u001b[0;32m    368\u001b[0m \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21;01mtyping\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mimport\u001b[39;00m Dict, Literal\n\u001b[0;32m    369\u001b[0m \u001b[38;5;28;01mclass\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21;01mPaperEvaluation\u001b[39;00m(BaseModel):\n",
      "\u001b[1;31mModuleNotFoundError\u001b[0m: No module named 'langchain.pydantic_v1'"
     ]
    }
   ],
   "source": [
    "ec_pred = api.run(\n",
    "    population = f\"Patients with {fin_condition} undergoing treatment with {treatements_eng[0]}\",\n",
    "    intervention = f\"{treatements_eng[0]}\",\n",
    "    comparator = \"\",\n",
    "    outcome = \"\",\n",
    "    llm = os.getenv(\"MODEL_NAME\"),\n",
    "    criteria = title_criteria + content_criteria,\n",
    "    papers = papers[:3], # make for the top-100 for demo\n",
    ")\n",
    "ec_pred"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "44cefd9e-0064-4e35-bc8a-b3bb9838fc4b",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "c69ff7c4-4e91-4afc-bdae-ec1fbf094012",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/41268440/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/41213063/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/40526090/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/40211189/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/40369167/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n"
     ]
    }
   ],
   "source": [
    "pmid_list = df_papers[0].PMID.values.tolist()\n",
    "#['41213063',#'26451310',]\n",
    "\n",
    "res = pmid2biocxml(pmid_list, api_key=pubmed_api_key)\n",
    "#print(res)\n",
    "res = [parse_bioc_xml(r) for r in res]\n",
    "# transform the parsed xml into paper content\n",
    "papers = []\n",
    "for parsed in res:\n",
    "    paper_content = []\n",
    "    for parsed_ in parsed[\"passage\"]:\n",
    "        paper_content.append(parsed_['content'])\n",
    "    paper_content = \"\\n\".join(paper_content)\n",
    "    papers.append(paper_content)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "3ac1dabb-884d-4bd7-9ce3-edd08f6c9e35",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[1672, 1652, 27171, 2627, 46819]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[len(i) for i in papers]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "6a9ab051-ac79-4050-93d9-7008b5074ed6",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Case Report: HGF and NF1 mutations as putative bypass mechanisms of MET inhibitor resistance in hepatocellular carcinoma: a case study.',\n",
       " 'Background: Hepatocellular carcinoma (HCC) is a highly aggressive liver cancer with poor prognosis, often associated with resistance to treatment. MET amplification has been identified as a potential therapeutic target, but resistance to MET inhibitors, such as crizotinib, remains a significant challenge. This study aims to explore the molecular mechanisms underlying resistance to MET inhibitors in MET-amplified HCC. Methods: We present a case of advanced HCC in a patient with MET amplification treated with crizotinib. After initial tumor regression, disease progression occurred. Genetic',\n",
       " 'challenge. This study aims to explore the molecular mechanisms underlying resistance to MET inhibitors in MET-amplified HCC. Methods: We present a case of advanced HCC in a patient with MET amplification treated with crizotinib. After initial tumor regression, disease progression occurred. Genetic analysis using next-generation sequencing (NGS) was performed on biopsy samples taken before and after progression to identify mutations associated with resistance. Results: NGS revealed the loss of MET amplification and identified HGF and NF1 mutations as potential bypass mechanisms. Specifically,',\n",
       " 'analysis using next-generation sequencing (NGS) was performed on biopsy samples taken before and after progression to identify mutations associated with resistance. Results: NGS revealed the loss of MET amplification and identified HGF and NF1 mutations as potential bypass mechanisms. Specifically, a missense mutation in HGF (p.G401A) was observed, which may enhance ligand-receptor binding, while an NF1 mutation (p.M546L) may permit sustained MAPK and PI3K activation despite MET inhibition. These observations are preliminary and require validation in larger patient cohorts. Conclusion: Our',\n",
       " 'a missense mutation in HGF (p.G401A) was observed, which may enhance ligand-receptor binding, while an NF1 mutation (p.M546L) may permit sustained MAPK and PI3K activation despite MET inhibition. These observations are preliminary and require validation in larger patient cohorts. Conclusion: Our findings suggest that acquired resistance to MET inhibitors in MET-amplified HCC may involve clonal evolution and activation of compensatory signaling pathways. These insights highlight the need for dynamic molecular surveillance and the development of strategies targeting multiple pathways to',\n",
       " 'Our findings suggest that acquired resistance to MET inhibitors in MET-amplified HCC may involve clonal evolution and activation of compensatory signaling pathways. These insights highlight the need for dynamic molecular surveillance and the development of strategies targeting multiple pathways to overcome resistance and improve patient outcomes.']"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "splited = split_text_into_chunks(papers[1], chunk_size=600,\n",
    "                                             chunk_overlap=300)\n",
    "splited"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "ac23d300-fc62-407f-8265-409a50f8a216",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "False\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[[{'name': 'Crizotinib treatment effectiveness',\n",
       "   'value': 'initial tumor regression followed by disease progression',\n",
       "   'source_id': [2],\n",
       "   'cited_blocks': ['challenge. This study aims to explore the molecular mechanisms underlying resistance to MET inhibitors in MET-amplified HCC. Methods: We present a case of advanced HCC in a patient with MET amplification treated with crizotinib. After initial tumor regression, disease progression occurred. Genetic analysis using next-generation sequencing (NGS) was performed on biopsy samples taken before and after progression to identify mutations associated with resistance. Results: NGS revealed the loss of MET amplification and identified HGF and NF1 mutations as potential bypass mechanisms. Specifically,']}],\n",
       " [{'name': 'Crizotinib effectiveness',\n",
       "   'value': 'More sensitive to low-risk group',\n",
       "   'source_id': [5],\n",
       "   'cited_blocks': ['performed in risk groups. Expression of signature genes in CRC cells was examined using quantitative reverse transcription polymerase chain reaction (qRT-PCR). There were 10 CRC-related RRAGs found. Prognostic models were built with RRAGs. Based on immune infiltration analysis, low-risk populations showed significantly greater levels of immune infiltration (P P ARHGEF17 mutation rate was 6%. Medications such as CGP-082996, Dasatinib, Erlotinib, and Salubrinal were more sensitive to high-risk group, whereas drugs such as FTI-277, DMOG, and Crizotinib were more sensitive to low-risk group.']}],\n",
       " [{'name': 'Crizotinib effectiveness',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'main_results_crizotinib',\n",
       "   'value': 'no objective responses observed in RASMT advanced CRC patients',\n",
       "   'source_id': [7],\n",
       "   'cited_blocks': ['with low baselineÂ\\xa0KRASMT allele frequency. CONCLUSIONS: Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients. EudraCT-Number: 2014-000463 -â\\x80\\x8940 (20/06/2014: A Sequential Phase I study of MEK1/2 inhibitors PD- 0325901 or Binimetinib combined with cMET inhibitor Crizotinib in RAS Mutant and RAS Wild Type with aberrant c-MET).']}],\n",
       " [{'name': 'Crizotinib_effectiveness',\n",
       "   'value': 'selectively inhibited the growth of ARID1A-deficient CRC cells',\n",
       "   'source_id': [80, 142],\n",
       "   'cited_blocks': ['validated the synthetic lethal effect of the c-MET inhibitor PHA-665752 (PHA) in two ARID1A knockout (ARID1A-KO) clones, where PHA selectively inhibited the growth of ARID1A-KO HCT116 cells (Fig.Â\\xa01D). Moreover, two FDA-approved c-MET inhibitors, crizotinib, and cabozantinib, also showed synthetic lethality in ARID1A-KO HCT116 clones (Fig.Â\\xa01E, F). These results suggest that c-MET is a potential synthetic lethal target for ARID1A in CRC cells.',\n",
       "    'synthetic lethality in ARID1A-deficient CRC. Notably, FDA-approved c-MET inhibitors, such as crizotinib and cabozantinib, have demonstrated enhanced cytotoxicity in ARID1A-deficient cancers, facilitating the translation of these approved drugs for repurposing in ARID1A-targeted precision cancer medicine.']}]]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "api = StudyCharacteristicsExtraction()\n",
    "extracted = api.run(\n",
    "    papers=papers,\n",
    "    fields=['Results, string, main results of the study regarding Crizotinib, usually about treatment effectiveness'],#api.DEFAULT_FIELDS,\n",
    "    llm='Qwen/Qwen3-32B',#\"openai-gpt-4o\",\n",
    "    chunk_size=600,\n",
    "    chunk_overlap=300,\n",
    "    thinking=False,\n",
    ")\n",
    "extracted"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "id": "dc85b6da-8fe9-4484-8430-e55e239b2525",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[[{'name': 'Crizotinib effectiveness',\n",
       "   'value': 'More sensitive to low-risk group',\n",
       "   'source_id': [4],\n",
       "   'cited_blocks': ['performed in risk groups. Expression of signature genes in CRC cells was examined using quantitative reverse transcription polymerase chain reaction (qRT-PCR). There were 10 CRC-related RRAGs found. Prognostic models were built with RRAGs. Based on immune infiltration analysis, low-risk populations showed significantly greater levels of immune infiltration (P P ARHGEF17 mutation rate was 6%. Medications such as CGP-082996, Dasatinib, Erlotinib, and Salubrinal were more sensitive to high-risk group, whereas drugs such as FTI-277, DMOG, and Crizotinib were more sensitive to low-risk group.']}],\n",
       " [{'name': 'Crizotinib treatment effectiveness',\n",
       "   'value': 'initial tumor regression followed by disease progression',\n",
       "   'source_id': [1],\n",
       "   'cited_blocks': ['challenge. This study aims to explore the molecular mechanisms underlying resistance to MET inhibitors in MET-amplified HCC. Methods: We present a case of advanced HCC in a patient with MET amplification treated with crizotinib. After initial tumor regression, disease progression occurred. Genetic analysis using next-generation sequencing (NGS) was performed on biopsy samples taken before and after progression to identify mutations associated with resistance. Results: NGS revealed the loss of MET amplification and identified HGF and NF1 mutations as potential bypass mechanisms. Specifically,']}]]"
      ]
     },
     "execution_count": 77,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "80601546-e32e-4b65-b837-b5dec0abdfc4",
   "metadata": {},
   "outputs": [],
   "source": [
    "llm_reasoning = ChatOpenAI(\n",
    "    base_url=BASE_URL,\n",
    "    api_key=HUGGINGFACE_HUB_TOKEN,\n",
    "    model=MODEL_NAME_HF,\n",
    "    streaming=True,\n",
    "    temperature=0,\n",
    "    #http_client=httpx_client\n",
    "    http_async_client=httpx.AsyncClient(verify=False)\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "87efd589-f082-4326-bc29-42ab4cd01c9a",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<think>\n",
      "\n",
      "</think>\n",
      "\n",
      "```json\n",
      "[\n",
      "    {\n",
      "        \"name\": \"Crizotinib effectiveness\",\n",
      "        \"value\": \"More sensitive to low-risk group\",\n",
      "        \"source_id\": [3]\n",
      "    }\n",
      "]\n",
      "```\n"
     ]
    }
   ],
   "source": [
    "prompt = ChatPromptTemplate.from_messages([\n",
    "    (\"user\", '/no_think {text}'),\n",
    "    # (\"ai\", \"Good.\")\n",
    "])\n",
    "\n",
    "chain = prompt | llm_reasoning\n",
    "response = await chain.ainvoke({\"text\": ff})\n",
    "\n",
    "#fin_condition = response.content.strip('<think>\\n\\n</think>\\n\\n')\n",
    "print(response.content)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python [conda env:llms]",
   "language": "python",
   "name": "conda-env-llms-py"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.19"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
